Gamal Mohamed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gamal Mohamed has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Abdulelah Almutairdi
Department of Internal Medicine, Division of Gastroenterology and Hepatology, King Faisal Specialist Hospital, Riyadh 11564, Saudi Arabia
1 shared publication - Abdulrahman Al Zhrani
Critical Care Medicine Department, King Faisal Specialist Hospital & Research Centre, Al Mathar Ash Shamali, Makkah Almukkramah branch road, Riyadh 11211, Saudi Arabia
1 shared publication - Ahood Alrashidi
Critical Care Medicine Department, King Faisal Specialist Hospital & Research Centre, Al Mathar Ash Shamali, Makkah Almukkramah branch road, Riyadh 11211, Saudi Arabia
1 shared publication - Amgad Alonazy
Department of Internal Medicine, King Faisal Specialist Hospital, Riyadh 11564, Saudi Arabia
1 shared publication - Ammar Almossalem
Critical Care Medicine Department, King Faisal Specialist Hospital & Research Centre, Al Mathar Ash Shamali, Makkah Almukkramah branch road, Riyadh 11211, Saudi Arabia
1 shared publication - Asma Sallam
Department of Internal Medicine, King Faisal Specialist Hospital, Riyadh 11564, Saudi Arabia
1 shared publication
Latest Publications
- 4 December 2025
- Published by Wiley in Epileptic Disorders
- Vol. 28 (2) , 295-303
“Who ‘nose’ when a seizure will happen?” Prodromal olfactory loss as a first clinical indicator of seizure activity in temporal lobe epilepsy
Objective: Olfactory dysfunction is well documented in neurological diseases, including temporal lobe epilepsy (TLE), where it may reflect dysfunction of limbic structures integral to both olfaction and seizure generation. While olfactory auras are classically recognized, their predictive utility in the preictal period remains unexplored. This study investigates transient olfactory impairment as a time‐sensitive prodromal marker preceding seizure onset in patients with TLE. Methods: Fifteen adults with confirmed or strongly suspected TLE were prospectively enrolled during admission to the Epilepsy Monitoring Unit at King Faisal Specialist Hospital and Research Centre in 2024. Olfactory function was assessed using the University of Pennsylvania Smell Identification Test (UPSIT) at baseline and every 6–8 h until seizure onset. Logistic regression was used to evaluate the association between olfactory dysfunction and time to seizure. Results: Seven of fifteen patients (46.7%) exhibited olfactory impairment prior to seizure onset. These patients experienced significantly shorter intervals between the last test and seizure onset (mean = 1.6 h) compared to those without impairment (mean = 4.1 h, p = 0.0145). Logistic regression revealed a significant inverse association between time and olfactory dysfunction likelihood (OR = 0.33 per hour, 95% CI: 0.09–0.73, p = 0.027), indicating olfactory impairment was more likely closer to seizure onset. Significance: This study is the first to quantitatively link prodromal olfactory dysfunction to seizure onset in TLE, identifying it as a potentially accessible, low‐cost, non‐invasive biomarker. These findings suggest a novel adjunct for seizure forecasting, and support future development of olfaction‐based prediction strategies. Larger scale studies are warranted to validate these results and investigate underlying mechanisms connecting olfactory circuits with ictogenesis.
- 4 December 2025
- Published by Wiley in Epileptic Disorders
- Vol. 28 (2) , 295-303
“Who ‘nose’ when a seizure will happen?” Prodromal olfactory loss as a first clinical indicator of seizure activity in temporal lobe epilepsy
Objective: Olfactory dysfunction is well documented in neurological diseases, including temporal lobe epilepsy (TLE), where it may reflect dysfunction of limbic structures integral to both olfaction and seizure generation. While olfactory auras are classically recognized, their predictive utility in the preictal period remains unexplored. This study investigates transient olfactory impairment as a time‐sensitive prodromal marker preceding seizure onset in patients with TLE. Methods: Fifteen adults with confirmed or strongly suspected TLE were prospectively enrolled during admission to the Epilepsy Monitoring Unit at King Faisal Specialist Hospital and Research Centre in 2024. Olfactory function was assessed using the University of Pennsylvania Smell Identification Test (UPSIT) at baseline and every 6–8 h until seizure onset. Logistic regression was used to evaluate the association between olfactory dysfunction and time to seizure. Results: Seven of fifteen patients (46.7%) exhibited olfactory impairment prior to seizure onset. These patients experienced significantly shorter intervals between the last test and seizure onset (mean = 1.6 h) compared to those without impairment (mean = 4.1 h, p = 0.0145). Logistic regression revealed a significant inverse association between time and olfactory dysfunction likelihood (OR = 0.33 per hour, 95% CI: 0.09–0.73, p = 0.027), indicating olfactory impairment was more likely closer to seizure onset. Significance: This study is the first to quantitatively link prodromal olfactory dysfunction to seizure onset in TLE, identifying it as a potentially accessible, low‐cost, non‐invasive biomarker. These findings suggest a novel adjunct for seizure forecasting, and support future development of olfaction‐based prediction strategies. Larger scale studies are warranted to validate these results and investigate underlying mechanisms connecting olfactory circuits with ictogenesis.
- Open Access
Prevalence and Impact of Zinc Deficiency on Clinical Outcomes in Inflammatory Bowel Disease
Background: Inflammatory bowel disease (IBD) can lead to zinc deficiency, which plays a critical role in immune function and tissue repair. This study aims to determine the prevalence, clinical characteristics, and impact of zinc deficiency in IBD patients. Methods: This is a retrospective study of patients aged ≥14 years with confirmed IBD and available zinc level measurement. Zinc deficiency was defined as a level p < 0.001) levels, and were more likely to be on corticosteroids (p = 0.04). Zinc deficiency was associated with higher rates of IBD-related hospitalizations (48.0% vs. 17.7%), surgeries (19.6% vs. 5.8%), complications (30.4% vs. 12.4%), and emergency room visits (40.2% vs. 17.3%) (all p < 0.001). Upon multivariate analysis, predictors of IBD-related hospitalization were zinc deficiency (OR 2.42, 95% CI 1.07–5.48, p = 0.03) and low albumin (OR 9.03, 95% CI 3.38–24.15, p < 0.001). Zinc deficiency was associated with IBD-related surgeries (OR 5.23, 95% CI 1.27–21.45, p = 0.02) and complications (OR 3.98, 95% CI 1.52–10.41, p = 0.005). Conclusions: Zinc deficiency is prevalent in patients with IBD, associated with a high inflammatory burden, and was linked to worse clinical outcomes after controlling for markers of inflammation.
Open AccessPrevalence and Impact of Zinc Deficiency on Clinical Outcomes in Inflammatory Bowel Disease
Background: Inflammatory bowel disease (IBD) can lead to zinc deficiency, which plays a critical role in immune function and tissue repair. This study aims to determine the prevalence, clinical characteristics, and impact of zinc deficiency in IBD patients. Methods: This is a retrospective study of patients aged ≥14 years with confirmed IBD and available zinc level measurement. Zinc deficiency was defined as a level p < 0.001) levels, and were more likely to be on corticosteroids (p = 0.04). Zinc deficiency was associated with higher rates of IBD-related hospitalizations (48.0% vs. 17.7%), surgeries (19.6% vs. 5.8%), complications (30.4% vs. 12.4%), and emergency room visits (40.2% vs. 17.3%) (all p < 0.001). Upon multivariate analysis, predictors of IBD-related hospitalization were zinc deficiency (OR 2.42, 95% CI 1.07–5.48, p = 0.03) and low albumin (OR 9.03, 95% CI 3.38–24.15, p < 0.001). Zinc deficiency was associated with IBD-related surgeries (OR 5.23, 95% CI 1.27–21.45, p = 0.02) and complications (OR 3.98, 95% CI 1.52–10.41, p = 0.005). Conclusions: Zinc deficiency is prevalent in patients with IBD, associated with a high inflammatory burden, and was linked to worse clinical outcomes after controlling for markers of inflammation.
- Open Access
- 24 December 2024
- Published by Elsevier in Endocrine Practice
- Vol. 31 (4) , 503-510
Insulin Degludec in Critically Ill Patients With Type 2 Diabetes Mellitus: A Prospective Interventional Study
- 24 December 2024
- Published by Elsevier in Endocrine Practice
- Vol. 31 (4) , 503-510
Open AccessInsulin Degludec in Critically Ill Patients With Type 2 Diabetes Mellitus: A Prospective Interventional Study